Realtime | Geld | Brief | Zeit |
---|---|---|---|
1,010 | 1,070 | 10:17 | |
1,010 | 1,060 | 10:05 |
Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
05.04. | NANOVIRICIDES, INC. - 8-K, Current Report | 2 | SEC Filings | ||
16.02. | NANOVIRICIDES, INC. - 8-K, Current Report | 1 | SEC Filings | ||
15.02. | NanoViricides GAAP EPS of -$0.18 | 1 | Seeking Alpha | ||
15.02. | NanoViricides, Inc.: NanoViricides Has Filed its Quarterly Report - NV-387 Clinical Trial Healthy Subjects Part Successfully Completed, COVID Patient Treatment on the Horizon | 927 | ACCESSWIRE | SHELTON, CT / ACCESSWIRE / February 15, 2024 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a global leader in broad-spectrum antiviral nanomedicines, reports that it has filed its Quarterly... ► Artikel lesen | |
14.02. | NANOVIRICIDES, INC. - 10-Q, Quarterly Report | - | SEC Filings | ||
01.02. | NanoViricides, Inc.: Clinical Trial Demonstration of Safety and Tolerability of NV-CoV-2 Has Implications Beyond COVID Treatment, Explains NanoViricides - NV-387 Could be As Revolutionary as Antibiotics | 807 | ACCESSWIRE | SHELTON, CT / ACCESSWIRE / February 1, 2024 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a leader in the development of highly effective antiviral therapies based on a novel nanomedicines... ► Artikel lesen | |
29.01. | NanoViricides reports positive safety results for COVID drug candidate | 1 | Seeking Alpha | ||
29.01. | NanoViricides, Inc.: Safety in Multiple-Ascending-Dose Healthy Subjects Clinical Trial Part Successfully Established for the NanoViricides Ultra-Broad-Spectrum Antiviral Drug NV-CoV-2 with No Adverse Events Found | 577 | ACCESSWIRE | SHELTON, CT / ACCESSWIRE / January 29, 2024 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a leader in the development of highly effective antiviral therapies based on a novel nanomedicines... ► Artikel lesen | |
19.01. | NANOVIRICIDES, INC. - 8-K, Current Report | 2 | SEC Filings | ||
08.01. | NanoViricides, Inc. (NNVC) To Unveil Cutting-Edge Antiviral Breakthroughs At Biotech Showcase 2024 | 2 | Benzinga.com | ||
04.01. | NanoViricides, Inc.: NanoViricides to Present at the Biotech Showcase in San Fransisco | 748 | ACCESSWIRE | SHELTON, CT / ACCESSWIRE / January 4, 2024 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a leader in the development of highly effective antiviral therapies based on a novel nanomedicines... ► Artikel lesen | |
28.11.23 | NanoViricides, Inc.: The Phase 1a/1b Human Clinical Trial of NV-CoV-2, the Company's Broad-Spectrum Antiviral Drug, Has Successfully Completed the First Part, Reports NanoViricides | 912 | ACCESSWIRE | SHELTON, CT / ACCESSWIRE / November 28, 2023 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a leader in the development of highly effective antiviral therapies based on a novel nanomedicines... ► Artikel lesen | |
15.11.23 | NanoViricides, Inc.: NanoViricides Has Filed its Quarterly Report - NV-387 Broad-Spectrum Antiviral in Clinical Trials Has Additional Applications | 1.064 | ACCESSWIRE | SHELTON, CT / ACCESSWIRE / November 15, 2023 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), reports that it has filed its Quarterly Report on Form 10-Q for the fiscal first quarter ending... ► Artikel lesen | |
14.11.23 | NanoViricides, Inc.: Broad-Spectrum Antiviral NV-387 in Phase 1a/1b Clinical Trial is Highly Effective in an Animal Model for MPox and Smallpox Drug Development | 601 | ACCESSWIRE | SHELTON, CT / ACCESSWIRE / November 14, 2023 / NanoViricides, Inc. (AMEX:NNVC) (the "Company"), a leader in the development of highly effective antiviral therapies based on a novel nanomedicines technology... ► Artikel lesen | |
16.10.23 | NanoViricides, Inc. Has Filed its Annual Report: Broad-spectrum Antiviral NV-387 in Phase 1a/1b Clinical Trial is Highly Active Against Coronaviruses as well as RSV | 753 | ACCESSWIRE | SHELTON, CT / ACCESSWIRE / October 16, 2023 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), reports that it has filed its Annual Report on Form 10-K for the fiscal year ending June 30, 2023... ► Artikel lesen | |
12.10.23 | NanoViricides, Inc. to Present at the Partnership Opportunities in Drug Delivery Conference in Boston on October 16, 2023 at 6:07pm ET | 670 | ACCESSWIRE | SHELTON, CT / ACCESSWIRE / October 12, 2023 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), announces that the Company's President, Dr. Anil Diwan, will be presenting a talk in person at... ► Artikel lesen | |
21.08.23 | NanoViricides, Inc.: The Phase 1a/1b Human Clinical Trial of NV-CoV-2, the Company's Broad-Spectrum Antiviral Drug, is Progressing Successfully, Reports NanoViricides | 1.133 | ACCESSWIRE | SHELTON, CT / ACCESSWIRE / August 21, 2023 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a leader in the development of highly effective antiviral therapies based on a novel nanomedicines... ► Artikel lesen | |
11.07.23 | NanoViricides, Inc.: Company's Broad-Spectrum Antiviral NV-387 Has Demonstrated Excellent Effectiveness in RSV in a Lethal Lung Disease Animal Model, Reports NanoViricides | 925 | ACCESSWIRE | SHELTON, CT / ACCESSWIRE / July 11, 2023 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a leader in the development of highly effective antiviral therapies based on a novel nanomedicines... ► Artikel lesen | |
06.07.23 | NanoViricides, Inc.: Clinical Trial of Broad-Spectrum Antiviral Drug NV-CoV-2 is Progressing Well, Says NanoViricides - NV-CoV-2 is Positioned to Fulfill Many Unmet Medical Needs | 692 | ACCESSWIRE | SHELTON, CO / ACCESSWIRE / July 6, 2023 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company") reports that the clinical trial of its broad-spectrum antiviral drug NV-CoV-2 is progressing satisfactorily.NanoViricides... ► Artikel lesen | |
29.06.23 | NanoViricides, Inc.: NanoViricides Announces that Clinical Trials of Its Broad-Spectrum Antiviral Drug NV-CoV-2 Have Begun | 776 | ACCESSWIRE | SHELTON, CT / ACCESSWIRE / June 29, 2023 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company") reports that clinical trials of its broad-spectrum antiviral drug NV-CoV-2 began on June 17, 2023... ► Artikel lesen |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
FORMYCON | 39,700 | 0,00 % | EQS-News: Formycon AG: Formycon lädt zur Telefonkonferenz zu den Ergebnissen des Geschäftsjahres 2023 ein und gibt Teilnahme an internationalen Investorenkonferenzen im 2. Quartal 2024 bekannt | EQS-News: Formycon AG
/ Schlagwort(e): Konferenz/Jahresergebnis
Formycon lädt zur Telefonkonferenz zu den Ergebnissen des Geschäftsjahres 2023 ein und gibt Teilnahme an internationalen... ► Artikel lesen | |
KOPIN | 0,776 | +2,44 % | Kopin Says Jury Awards Damages Of About $24.8 Mln To BlueRadios | WASHINGTON (dpa-AFX) - Kopin Corp., Inc. (KOPN) announced Tuesday that a jury verdict was entered on Monday in the U.S. District Court for the District of Colorado finding for the plaintiff... ► Artikel lesen | |
NANOFOCUS | 0,300 | 0,00 % | Nanofocus: Investor verlängert die Frist | Die Carl Mahr Holding hat im März ein freiwilliges öffentliches Erwerbsangebot für die Aktien von Nanofocus abgegeben. Geboten werden dabei 0,50 Euro je Aktie von Nanofocus. Ursprünglich konnten Investoren... ► Artikel lesen | |
VEECO INSTRUMENTS | 31,800 | 0,00 % | Veeco Instruments Inc.: Veeco Reports Fourth Quarter and Fiscal Year 2023 Financial Results | Fourth Quarter 2023 Highlights: Revenue of $173.9 million, compared with $153.8 million in the same period last yearGAAP net income of $21.6 million, or $0.37 per diluted share, compared with $128.9... ► Artikel lesen | |
ACACIA RESEARCH | 4,480 | -0,88 % | Acacia Research Reports Fourth Quarter 2023 Financial Results | NEW YORK--(BUSINESS WIRE)--Acacia Research Corporation (Nasdaq: ACTG) ("Acacia" or the "Company") today reported financial results for the three months and full year ended December 31, 2023.
Martin... ► Artikel lesen | |
ADVANCE ZINCTEK | 0,515 | +1,98 % | ADVANCE ZINCTEK LIMITED: US Sales | ||
LEHNER INVESTMENTS | 0,064 | -28,49 % | EQS-News: LEHNER INVESTMENTS AG - Neuer Vorstand, Wechsel im Aufsichtsrat | EQS-News: LEHNER INVESTMENTS AG
/ Schlagwort(e): Personalie
LEHNER INVESTMENTS AG - Neuer Vorstand, Wechsel im Aufsichtsrat
24.04.2024 / 11:24 CET/CEST
Für den Inhalt... ► Artikel lesen | |
RIBER | 2,650 | -1,49 % | Riber: 2024 first quarter revenues: +20% | ||
DOTZ NANO | 0,070 | +6,11 % | DOTZ NANO LIMITED: Change of Auditor | ||
ZENTEK | 0,980 | -7,55 % | Zentek Ltd.: Zentek Provides ZenGUARD Business Update | GUELPH, ON / ACCESSWIRE / April 25, 2024 / Zentek Ltd. ("Zentek" or the "Company") (Nasdaq:ZTEK)(TSX-V:ZEN), an intellectual property technology development and commercialization company is pleased... ► Artikel lesen | |
GOMSPACE | 0,344 | 0,00 % | GomSpace A/S: GomSpace receives order for cutting-edge products from diverse customers at a total value of €923.000 (approx. 10.8MSEK) | STOCKHOLM, Oct. 31, 2023 /PRNewswire/ -- GomSpace gives an update on its product business and announces that the company has received, since the last press release on September 21, new product... ► Artikel lesen | |
REGION GROUP | 1,278 | 0,00 % | REGION GROUP: Change in substantial holding | ||
XTPL | 31,300 | -1,57 % | XTPL baut mit Chinas führendem Hersteller von Maschinen für die FPD-Industrie ein industrielles Prototypgerät | Breslau, Polen (ots/PRNewswire) - XTPL führt einen fünften Verkauf eines Moduls für industrielle Anwendungen durch. Der Endkunde ist ein führender chinesischer Hersteller von Maschinen für die Flachbildschirmindustrie... ► Artikel lesen | |
NANOFORM FINLAND | 2,000 | -7,41 % | NANOFORM: Disclosure of Major Holdings under Law 163/2024 | ||
INSPLORION | 0,203 | +1,50 % | Nasdaq Stockholm AB: New equity rights for trading, Insplorion AB (publ) (625/23) | At the request of Insplorion AB (publ), equity rights will be traded on First
North as from December 5, 2023.
Security name: Insplorion AB TO2
Short name: INSP TO2
ISIN code: SE0020999175... ► Artikel lesen |